Cansino Biologics, Inc. Class ASSE: 688185

Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical Trial

· Issued by Cansino Biologics, Inc. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical Trial

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis